Agios Pharmaceuticals Inc (NASDAQ:AGIO) was the recipient of some unusual options trading activity on Thursday. Stock traders acquired 1,012 put options on the stock. This represents an increase of approximately 1,410% compared to the typical volume of 67 put options.
AGIO stock traded down $0.17 during trading on Friday, hitting $39.69. The company had a trading volume of 8,734 shares, compared to its average volume of 623,397. The firm has a market capitalization of $2.76 billion, a price-to-earnings ratio of -7.51 and a beta of 2.03. The business has a 50 day moving average of $48.73 and a 200 day moving average of $46.35. Agios Pharmaceuticals has a fifty-two week low of $27.77 and a fifty-two week high of $56.74. The company has a current ratio of 13.15, a quick ratio of 12.98 and a debt-to-equity ratio of 0.18.
Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.05. Agios Pharmaceuticals had a negative net margin of 182.49% and a negative return on equity of 59.71%. The business had revenue of $37.30 million during the quarter, compared to the consensus estimate of $37.17 million. During the same quarter in the prior year, the company posted ($1.87) earnings per share. The company’s quarterly revenue was up 42.4% compared to the same quarter last year. As a group, equities analysts predict that Agios Pharmaceuticals will post -4.63 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Pearl River Capital LLC acquired a new stake in Agios Pharmaceuticals in the 1st quarter valued at about $32,000. Advisor Group Holdings Inc. lifted its holdings in Agios Pharmaceuticals by 427.9% in the 2nd quarter. Advisor Group Holdings Inc. now owns 1,267 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 1,027 shares during the last quarter. Captrust Financial Advisors acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $75,000. Citizens Financial Group Inc RI lifted its holdings in Agios Pharmaceuticals by 919.3% in the 2nd quarter. Citizens Financial Group Inc RI now owns 1,478 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 1,333 shares during the last quarter. Finally, Parallel Advisors LLC lifted its holdings in Agios Pharmaceuticals by 1,510.3% in the 2nd quarter. Parallel Advisors LLC now owns 1,562 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,465 shares during the last quarter. 97.73% of the stock is owned by institutional investors.
Several research firms have weighed in on AGIO. Piper Sandler boosted their target price on shares of Agios Pharmaceuticals from $70.00 to $80.00 and gave the company an “overweight” rating in a research note on Friday, June 12th. Citigroup boosted their price target on shares of Agios Pharmaceuticals from $64.00 to $75.00 and gave the company a “buy” rating in a report on Monday, June 15th. Guggenheim boosted their price target on shares of Agios Pharmaceuticals from $60.00 to $66.00 and gave the company a “buy” rating in a report on Monday, June 15th. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating and set a $56.00 price target for the company. in a report on Tuesday, June 16th. Finally, BidaskClub downgraded shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $68.77.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Read More: Total Return
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.